pyrazines has been researched along with B-Cell Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Ran, F; Wang, ML; Yang, D; Zhang, D; Zhang, Z; Zhao, G | 1 |
| Delić, J; Gobec, M; Markovič, T; Mlinarič-Raščan, I; Prijatelj, M | 1 |
| Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J | 1 |
| Bastian, L; Eckert, C; Fichtner, I; Henze, G; Hof, J; Pfau, M; Prada, J; Seeger, K; Shalapour, S; von Stackelberg, A | 1 |
| Schenkein, D | 1 |
2 review(s) available for pyrazines and B-Cell Leukemia
| Article | Year |
|---|---|
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Drug Design; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
1 trial(s) available for pyrazines and B-Cell Leukemia
| Article | Year |
|---|---|
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure | 2011 |
2 other study(ies) available for pyrazines and B-Cell Leukemia
| Article | Year |
|---|---|
Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.
Topics: Alprostadil; Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Jurkat Cells; Leukemia, B-Cell; Lymphoma, B-Cell; NF-kappa B; Pyrazines; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; U937 Cells | 2014 |
Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Leukemia, B-Cell; Mice; NF-kappa B; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription Factor RelA; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |